智通财经APP讯，领航医药生物科技(00399)发布公告，于2025年8月21日(联交所交易时段结束后)，本公司与配售代理订立配售协议，配售代理已有条件同意担任本公司代理，以竭诚促使目前预期不少于六名承配人(彼等及其最终实益拥有人应为独立第三方)按每股配售股份0.415港元的配售价认购最多1.45亿股配售股份。
假设本公司已发行股本于本公告日期至完成配售事项日期期间不会有变，最多1.45亿股配售股份占扩大后已发行股本约6.34%。每股配售股份0.415港元的配售价较2025年8月21日收市价每股0.46港元折让约9.78%。
假设所有配售股份获悉数配售，配售事项所得款项总额将约为6017.5万港元。扣除配售事项附带的所有相关开支(包括但不限于配售佣金、法律开支及代垫费用)约135万港元后，所得款项净额估计约为5882.5万港元。本公司拟将配售事项所得款项净额全数用作本集团的于发展区块链技术业务资金。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.